drugset

drugset / Trial / NCT06225635

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab

NCT06225635 ↗

Phase 1 Completed 60 enrolled Shin Poong Pharmaceutical Co. Ltd.

RandomizedCrossoverOpen-labelTreatment

Summary

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab

Timeline

Start: 2022-01-01
Primary completion: 2022-03-07
Completion: 2022-03-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ezetimibe	Unknown	10 mg	—
Subject	Rosuvastatin	Small molecule	20 mg	—

Indications